Gemmell H G, Sharp P F, Besson J A, Crawford J R, Ebmeier K P, Davidson J, Smith F W
J Comput Assist Tomogr. 1987 May-Jun;11(3):398-402. doi: 10.1097/00004728-198705000-00005.
One of the potential clinical uses of the new cerebral blood flow agent 99mTc-hexamethylpropyleneamineoxime (HM-PAO) is the investigation of dementia, in particular to differentiate between dementia of the Alzheimer type (DAT) and multiinfarct dementia (MID). In this study 27 patients, 17 with DAT and 10 with MID, and three normal volunteers were imaged both with single photon emission CT and magnetic resonance. The HM-PAO perfusion deficits were much more common in the DAT group than in the MID group, especially in the temporoparietooccipital (TPO) regions. The two groups of patients were found to be significantly different (p less than 0.02), as regards the frequency of occurrence of bilateral TPO perfusion deficits. Four of the 17 DAT patients did not have bilateral TPO deficits but these included the three least impaired patients as assessed by psychometric testing.
新型脑血流显像剂99mTc-六甲基丙烯胺肟（HM-PAO）的潜在临床应用之一是对痴呆进行研究，尤其是区分阿尔茨海默型痴呆（DAT）和多发梗死性痴呆（MID）。在本研究中，对27例患者（17例DAT患者和10例MID患者）以及3名正常志愿者进行了单光子发射计算机断层扫描和磁共振成像检查。HM-PAO灌注缺损在DAT组比MID组更为常见，尤其是在颞顶枕（TPO）区域。就双侧TPO灌注缺损的发生频率而言，发现两组患者存在显著差异（p<0.02）。17例DAT患者中有4例没有双侧TPO缺损，但这些患者包括心理测量测试评估中受损最轻的3例患者。
